Market Research Logo

Dyskinesia - Pipeline Review, H2 2016

Dyskinesia - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Dyskinesia - Pipeline Review, H2 2016’, provides an overview of the Dyskinesia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Dyskinesia
    • The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects
    • The report assesses Dyskinesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Dyskinesia
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Dyskinesia
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Dyskinesia Overview
    Therapeutics Development
    Pipeline Products for Dyskinesia - Overview
    Pipeline Products for Dyskinesia - Comparative Analysis
    Dyskinesia - Therapeutics under Development by Companies
    Dyskinesia - Therapeutics under Investigation by Universities/Institutes
    Dyskinesia - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Dyskinesia - Products under Development by Companies
    Dyskinesia - Products under Investigation by Universities/Institutes
    Dyskinesia - Companies Involved in Therapeutics Development
    Adamas Pharmaceuticals, Inc.
    Addex Therapeutics Ltd
    Advicenne
    Astraea Therapeutics, LLC
    Bionomics Limited
    Catalyst Biosciences, Inc.
    Catalyst Pharmaceuticals, Inc.
    Clevexel Pharma SAS
    Contera Pharma ApS
    EpiVax, Inc.
    Heptares Therapeutics Limited
    Hua Medicine (Shanghai) Ltd.
    Integrative Research Laboratories Sweden AB
    Ipsen S.A.
    Merz Pharma GmbH & Co. KgaA
    MitoDys Therapeutics Limited
    Neurim Pharmaceuticals Ltd
    Neurocrine Biosciences, Inc.
    Neurolixis Inc.
    Osmotica Pharmaceutical Corp.
    Otsuka Holdings Co., Ltd.
    Phenomenome Discoveries, Inc.
    Revance Therapeutics, Inc.
    Sage Therapeutics, Inc.
    SciFluor Life Sciences, LLC
    SOM Innovation Biotech SL
    Synchroneuron Inc.
    Teva Pharmaceutical Industries Ltd.
    Dyskinesia - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (dextromethorphan + quinidine sulfate) - Drug Profile
    A2M-13677 - Drug Profile
    abobotulinumtoxin A - Drug Profile
    acamprosate calcium SR - Drug Profile
    amantadine hydrochloride ER - Drug Profile
    amantadine hydrochloride ER - Drug Profile
    AT-127 - Drug Profile
    AT-326 - Drug Profile
    AT-403 - Drug Profile
    befiradol - Drug Profile
    CPP-115 - Drug Profile
    CVXL-0107 - Drug Profile
    deutetrabenazine ER - Drug Profile
    dipraglurant ER - Drug Profile
    dipraglurant IR - Drug Profile
    Drug for Dyskinesia - Drug Profile
    HTL-14242 - Drug Profile
    incobotulinumtoxin A - Drug Profile
    IRL-790 - Drug Profile
    JM-010 - Drug Profile
    MLR-1019 - Drug Profile
    NBI-640756 - Drug Profile
    Neu-120 - Drug Profile
    Neu-240 - Drug Profile
    onabotulinumtoxinA - Drug Profile
    PEUN-3 - Drug Profile
    PPI-1011 - Drug Profile
    remeglurant - Drug Profile
    RT-002 - Drug Profile
    SAGE-217 - Drug Profile
    sepranolone - Drug Profile
    SK-609 - Drug Profile
    Small Molecule for Dyskinesia - Drug Profile
    Small Molecule for Dyskinesia and Hyperkinesia - Drug Profile
    Small Molecules for Neurodegenerative Disease - Drug Profile
    Small Molecules for Tardive Dyskinesia - Drug Profile
    Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile
    Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile
    Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile
    Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile
    Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile
    SOM-3355 - Drug Profile
    TC-8831 - Drug Profile
    tetrabenazine - Drug Profile
    valbenazine tosylate - Drug Profile
    Dyskinesia - Dormant Projects
    Dyskinesia - Discontinued Products
    Dyskinesia - Product Development Milestones
    Featured News & Press Releases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Dyskinesia, H2 2016
    Number of Products under Development for Dyskinesia - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Investigation by Universities/Institutes, H2 2016
    Dyskinesia - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016
    Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2016
    Dyskinesia - Pipeline by Advicenne, H2 2016
    Dyskinesia - Pipeline by Astraea Therapeutics, LLC, H2 2016
    Dyskinesia - Pipeline by Bionomics Limited, H2 2016
    Dyskinesia - Pipeline by Catalyst Biosciences, Inc., H2 2016
    Dyskinesia - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016
    Dyskinesia - Pipeline by Clevexel Pharma SAS, H2 2016
    Dyskinesia - Pipeline by Contera Pharma ApS, H2 2016
    Dyskinesia - Pipeline by EpiVax, Inc., H2 2016
    Dyskinesia - Pipeline by Heptares Therapeutics Limited, H2 2016
    Dyskinesia - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016
    Dyskinesia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016
    Dyskinesia - Pipeline by Ipsen S.A., H2 2016
    Dyskinesia - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016
    Dyskinesia - Pipeline by MitoDys Therapeutics Limited, H2 2016
    Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016
    Dyskinesia - Pipeline by Neurocrine Biosciences, Inc., H2 2016
    Dyskinesia - Pipeline by Neurolixis Inc., H2 2016
    Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp., H2 2016
    Dyskinesia - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
    Dyskinesia - Pipeline by Phenomenome Discoveries, Inc., H2 2016
    Dyskinesia - Pipeline by Revance Therapeutics, Inc., H2 2016
    Dyskinesia - Pipeline by Sage Therapeutics, Inc., H2 2016
    Dyskinesia - Pipeline by SciFluor Life Sciences, LLC, H2 2016
    Dyskinesia - Pipeline by SOM Innovation Biotech SL, H2 2016
    Dyskinesia - Pipeline by Synchroneuron Inc., H2 2016
    Dyskinesia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Dyskinesia - Dormant Projects, H2 2016
    Dyskinesia - Dormant Projects (Contd..1), H2 2016
    Dyskinesia - Dormant Projects (Contd..2), H2 2016
    Dyskinesia - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Dyskinesia, H2 2016
    Number of Products under Development for Dyskinesia - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report